Tissue Factor definition

Tissue Factor means the antigen having the NCBI Entrez Gene Symbol of F3 and an amino acid sequence corresponding to NCBI RefSeq accession number NP-001984, [***].
View Source
Tissue Factor means the antigen having the NCBI Entrez Gene Symbol of F3 and an amino acid sequence corresponding to NCBI RefSeq accession number NP-001984, [ * ]. 1.1.129 “Third Party” means any person or entity other than Genmab, SGI and their respective Affiliates. 1.1.130 “Third Party Collaboration Agreement” means any agreement pursuant to which a Third Party is granted rights to commercialize (including to develop and commercialize) one or more Collaboration Products, including development agreements, collaboration agreements, marketing and marketing/distribution agreements, promotion agreements or other similar agreements, in each case in accordance with the provisions of Section 5.11. 1.1.131 “Unilateral Product” has the meaning set forth in Section 5.10. For clarity, a Unilateral Product must be within the definition of Licensed Product. 1.1.132 “Valid Patent Claim” means (a) an unexpired claim of an issued patent (including any extension thereof pursuant to patent term extension or a supplementary protection certification) which has not been found to be unpatentable, invalid or unenforceable by an unreversed and unappealable decision (including a decision that was not appealed within the time allotted for an appeal) of a court or other authority in the subject country; or (b) a claim of an application for a patent that has been [ * ].
View Source

Examples of Tissue Factor in a sentence

  • Genmab shall not have the right to sublicense the SGI Technology outside the scope of the license granted in Section 2.1.1 or 2.1.3, including no rights to develop further SGI Technology on a stand-alone basis or make or use SGI Technology to create antibody-drug conjugates that include or are based upon any antibodies that bind specifically to an antigen other than Tissue Factor.

  • After the Closing Date, in conjunction with the delivery of Assets to Purchaser hereunder, Seller shall provide to Purchaser copies of books, files, documents, records, laboratory notebooks, databases, reports, and other documentation and materials embodying any Licensed Tissue Factor Antagonist Know-How.

  • Seller may retain copies of books, files, documents, records, laboratory notebooks, databases, reports, and other documentation and materials embodying any Seller Tissue Factor Antagonist Know-How (other than Seller Tissue Factor Antagonist Know-How that is related solely to the Tissue Factor Antagonists).

  • Seller has made available to Purchaser true and correct copies of all written communications by or on behalf of or at the request of Seller with the FDA and all other Regulatory Authorities with respect to any Tissue Factor Antagonist, as well as copies of any notes relative to oral discussions.

  • There are no interference action Proceedings pending, or any written communication that threatens an interference action, or other Proceeding (not including any office action or responses thereto or any Proceedings involving the FDA in the ordinary course), before any patent and trademark office or any Government Authority in any jurisdiction in regard to any Assigned Patent Rights or, to the knowledge of Seller, any Seller Tissue Factor Antagonist Know-How or Licensed Tissue Factor Antagonist Know-How.

  • There are no Patent Rights of which Seller is aware that describe or claim Tissue Factor Antagonists, which Patent Rights are not owned by Seller but are Controlled by Seller.

  • Seller is and at all times has been in compliance in all material respects with all Legal Requirements related to the research, development, and/or manufacture of any Tissue Factor Antagonists by or for Seller.

  • Notwithstanding anything to this Agreement to the contrary, and, subject to applicable Legal Requirements, Purchaser, its Affiliates, and its Affiliates’ sublicensees shall not refer publicly to Seller or Altor (including their employees, agents, boards members and officers) by name or in any form of promotion or in connection with the sale of Tissue Factor Antagonists without the prior written consent of such Party.

  • To Seller’s knowledge, no Third Party that conducted preclinical or clinical studies on Seller’s behalf has made, without Seller’s permission or request, any filings with the FDA or any other Regulatory Authority with respect to any Tissue Factor Antagonist.

  • Upon assignment of an Assumed Contract to Purchaser hereunder, Seller shall provide to Purchaser copies of those books, files, documents, records, laboratory notebooks, databases, reports, and other documentation and materials (if any) that embody the Tissue Factor Antagonists and/or Tissue Factor Antagonist Know-How (if any) in Seller’s possession that were licensed to Seller under such Assumed Contract.

Related to Tissue Factor

  • Note Factor means, with respect to the Notes or any Class of Notes on any Payment Date, a six-digit decimal figure equal to the Note Balance of the Notes or such Class of Notes, as applicable, as of the end of the preceding Collection Period divided by the Note Balance of the Notes or such Class of Notes, as applicable, as of the Closing Date. The Note Factor will be 1.000000 as of the Closing Date; thereafter, the Note Factor will decline to reflect reductions in the Note Balance of the Notes or such Class of Notes, as applicable.

  • Leverage Factor means the leverage factor in respect of a Series of ETP Securities as specified in the relevant Final Terms.

  • Technique factors means the following conditions of operation:

  • Fit factor means a quantitative estimate of the fit of a particular respirator to a specific individual, and typically estimates the ratio of the concentration of a substance in ambient air to its concentration inside the respirator when worn.

  • Exchange Factor means 1.0; provided, however, that if the General Partner: (a) declares or pays a dividend on its outstanding Common Stock in Common Stock or makes a distribution to all holders of its outstanding Common Stock in Common Stock; (b) subdivides its outstanding Common Stock; or (c) combines its outstanding Common Stock into a smaller number of shares of Common Stock, the Exchange Factor shall be adjusted by multiplying the Exchange Factor by a fraction, the numerator of which shall be the number of shares of Common Stock issued and outstanding on the record date for such dividend, contribution, subdivision or combination (assuming for such purpose that such dividend, distribution, subdivision or combination has occurred as of such time), and the denominator of which shall be the actual number of shares of Common Stock (determined without the above assumption) issued and outstanding on the record date for such dividend, distribution, subdivision or combination. Any adjustment to the Exchange Factor shall become effective immediately after the effective date of such event retroactive to the record date, if any, for such event.